Solid Biosciences
SLDB
91 hedge funds and large institutions have $184M invested in Solid Biosciences in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 30 reducing their positions, and 15 closing their positions.
8% more call options, than puts
Call options by funds: $567K | Put options by funds: $527K
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
0.19% less ownership
Funds ownership: 4.85% → 4.65% (-0.19%)
1% less funds holding
Funds holding: 92 → 91 (-1)
27% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 30
37% less capital invested
Capital invested by funds: $293M → $184M (-$109M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$2.12M |
| 2 |
BlackRock
New York
|
+$1.25M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.05M |
| 4 |
Goldman Sachs
New York
|
+$750K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$337K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$3.4M |
| 2 |
Two Sigma Advisers
New York
|
-$2.65M |
| 3 |
Two Sigma Investments
New York
|
-$2.62M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
-$1.42M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.18M |
SLDB Hedge Fund Activity: Q3 2021 in Review
91 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q3 2021, worth a combined $184M — down 37% from $293M a quarter earlier.
Fund positioning in SLDB was balanced in Q3 2021: 15 funds opened new positions, 15 closed out, 22 added to existing stakes and 30 trimmed.
The largest buyer was Artal Group, adding an estimated $2.12M. The largest seller was Marshall Wace North America, cutting an estimated $3.4M.
- 91 institutional investors held Solid Biosciences (SLDB) as of Q3 2021, down from 92 in Q2 2021.
- Funds reported $184M of Solid Biosciences stock for Q3 2021, down 37% quarter-over-quarter.
- 15 funds opened new Solid Biosciences positions in Q3 2021 and 15 closed out, a net change of 0 holders.
- The largest Solid Biosciences buyer in Q3 2021 was Artal Group, an estimated $2.12M added.
- The largest Solid Biosciences seller in Q3 2021 was Marshall Wace North America, an estimated $3.4M sold.
Based on aggregated 13F filings for Q3 2021.